← TrialMatch
HomeTrials

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

This is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual FIX levels and aged 12-18 years old. BBM-H901 is an adeno-associated viral (AAV) vector des

Condition(s)Hemophilia B
StatusRecruiting
PhasePhase 1
Study typeInterventional
SummaryThis is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual FIX levels and aged 12-18 years old. BBM-H901 is an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene and raise circulating levels of endogenous FIX.
Who can participateInclusion Criteria: 1. Subjects and statutory guardian must be able to understand the purpose and risks of the study and provide signed and dated informed consent; 2. Be male and 12≤ age \<18 years of age, body wight ≥ 50kg; 3. Have hemophilia B with ≤2 IU/dL (≤2 %) endogenous FIX activity levels as documented by a certified clinical laboratory at the time of screening. If the screening result is \>2% due to insufficient washout from FIX protein product, then the severity of hemophilia B may be confirmed by documented historical evidence from a certified clinical laboratory demonstrating ≤2% FIX coagulant activity (FIX:C) ; 4. Had had ≥75 prior exposure days (EDs) to any recombinant and/or plasma-derived FIX protein products based on historical data from the subject's record/history; 5. Wi
Ages12 Years to 18 Years
SexMale
Lead sponsorInstitute of Hematology & Blood Diseases Hospital, China
LocationsTianjin, Tianjin Municipality, China
Start date2023-03-23
NCT IDNCT05709288
Official listinghttps://clinicaltrials.gov/study/NCT05709288

🔍 Search all trials →